GlassScriptPhysician profile
Aleksandr Batikov
NPI 1629058706
$17,646.77
in general payments reported to CMS, 2019-2025
30 companies · $2,896 in 2025
The $2,896 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,488 · 2020: $2,310 · 2021: $2,189 · 2022: $2,397 · 2023: $1,111 · 2024: $2,255 · 2025: $2,896.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,262.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,262.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,430.93 | 2019-2025 | Creon |
| Amgen INC. | $2,886.85 | 2019-2025 | Evenity, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,470.10 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $1,421.16 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $830.92 | 2019-2020 | |
| Genzyme Corporation | $732.82 | 2019-2024 | |
| Teva Pharmaceuticals USA, INC. | $608.90 | 2019-2025 | Austedo Xr |
| Alkermes, INC. | $507.01 | 2020-2025 | Lybalvi |
| Lilly USA, LLC | $491.35 | 2022-2025 | Mounjaro, Zepbound |
| Regeneron Healthcare Solutions, INC. | $481.88 | 2019-2023 | Dupixent |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $477.68 | 2019-2025 | Xifaxan |
| Allergan, INC. | $379.47 | 2019-2020 | |
| Amarin Pharma, INC. | $374.91 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $372.14 | 2019-2020 | |
| Glaxosmithkline, LLC. | $358.52 | 2019-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $352.22 | 2019-2022 | |
| Medtronic, INC. | $282.48 | 2022 | |
| Ardelyx, INC. | $265.05 | 2024-2025 | Ibsrela |
| Aimmune Therapeutics, INC. | $249.97 | 2024-2025 | Zenpep |
| Axsome Therapeutics, INC. | $245.39 | 2025 | Auvelity |
| Sanofi-Aventis U.S. LLC | $226.58 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $218.75 | 2019-2020 | |
| Scilex Pharmaceuticals INC. | $149.98 | 2024 | |
| Pharmacosmos Therapeutics INC. | $125.00 | 2023 | Monoferric |
| Merck Sharp & Dohme LLC | $125.00 | 2023 | Verquvo |
| Biohaven Pharmaceuticals, INC. | $124.89 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $124.20 | 2021 | |
| Amneal Pharmaceuticals LLC | $121.58 | 2025 | Crexont |
| Sk Life Science, INC. | $109.54 | 2025 | Xcopri |
| Antares Pharma, INC. | $101.50 | 2023 | Xyosted, Tlando |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aleksandr Batikov listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.